MINYANVILLE ORIGINAL As the world awaited results from the US presidential election Pfizer (NYSE:PFE) scored its own victory Tuesday with the approval of a pill that treats rheumatoid arthritis. With Xeljanz Pfizer is believed to have a potential blockbuster -- a drug that potentially generates a few billion dollars a year in revenue according to Wall Street analysts. Speculation by analysts also focuses on how much market share Pfizer can take from existing injected rheumatoid arthritis drugs including Amgen’s (NASDAQ:AMGN) Enbrel Johnson & Johnson’s (NYSE:JNJ) Remicade and the big gorilla Abbott Laboratories’ (NYSE:ABT) Humira. (Pfizer is unwinding a sales ...